Frazier Life Sciences Management L.P. Invests $19.91 Million in Ascendis Pharma A/S (NASDAQ:ASND)

Frazier Life Sciences Management L.P. purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 133,333 shares of the biotechnology company’s stock, valued at approximately $19,908,000. Ascendis Pharma A/S accounts for 0.8% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 28th largest position. Frazier Life Sciences Management L.P. owned 0.22% of Ascendis Pharma A/S as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ASND. SG Americas Securities LLC lifted its stake in shares of Ascendis Pharma A/S by 221.0% during the 2nd quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock worth $833,000 after buying an additional 4,205 shares during the last quarter. Legato Capital Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 167.6% during the second quarter. Legato Capital Management LLC now owns 4,324 shares of the biotechnology company’s stock worth $590,000 after acquiring an additional 2,708 shares during the period. Searle & CO. acquired a new position in shares of Ascendis Pharma A/S in the second quarter valued at approximately $205,000. Rhumbline Advisers increased its stake in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares during the period. Finally, Candriam S.C.A. increased its stake in shares of Ascendis Pharma A/S by 96.6% during the second quarter. Candriam S.C.A. now owns 195,347 shares of the biotechnology company’s stock worth $26,640,000 after purchasing an additional 95,972 shares during the period.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $132.42 on Tuesday. The firm has a 50 day simple moving average of $130.19 and a two-hundred day simple moving average of $132.69. Ascendis Pharma A/S has a one year low of $101.43 and a one year high of $161.00. The company has a market cap of $8.03 billion, a P/E ratio of -16.39 and a beta of 0.67.

Analyst Ratings Changes

A number of research analysts have commented on ASND shares. JPMorgan Chase & Co. decreased their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. The Goldman Sachs Group boosted their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Finally, Jefferies Financial Group raised their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus price target of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.